![Page 1: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/1.jpg)
How I treat my
Cancer Associated Thrombosis
Avi Leader, MD
Hematology Institute, Rabin Medical Center
May 2020
![Page 2: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/2.jpg)
Epidemiology• Cancer increases risk of VTE by 4-6 fold
• About 20% of VTE cases occur in cancer patients
• A cancer patient has a ~15% likelihood of suffering a VTE event during his cancer journey
• VTE patients with cancer have increased rates of major and clinically relevant non-major bleeding (9.2%) and recurrent thrombosis (7.6%) compared to VTE patients without cancer (2.0% and 2.1%, respectively, RIETE data)
• VTE is the second leading cause of death in cancer patients
• Increased incidence of arterial thrombosis
![Page 3: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/3.jpg)
1Mosarla, JACC 2019
Pathogenesis of increased thrombotic risk in cancer
![Page 4: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/4.jpg)
Overview
1. Preventing thrombosis in cancer outpatients– Risk assessment– LMWH vs. DOAC as thromboprophylaxis
2. Treating cancer-associated VTE in the DOAC era
3. Practical aspects of AC management (in CAT)
4. Treating recurrent VTE
5. Approach to DIC
6. Arterial thrombosis in cancer
![Page 5: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/5.jpg)
Case #1
• 55 year old male with no prior medical Hx
• Newly diagnosed locally advanced pancreatic cancer– External tumor compression of splenic vein and SMV
– Candidate for ambulatory chemotherapy (mFOLFIRINOX)
• ECOG1 | BMI = 26
• WBC = 9K/µL | PLT = 150K/µL | Hb = 10.8 gr%
• Creatinine, liver enzymes and albumin = normal
• PTT, PT, Fibrinogen normal
Thrombotic risk? Anticoagulation indicated? What else?
![Page 6: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/6.jpg)
Risk assessment in cancer outpatients: Khorana Score
Khorana, Blood 2008; Ay, Blood 2010; Khorana, Thr Res, 2018; van Es, JTH 2020
VTE @ 6 months• High ≥ 3 = 17.7%• Int-High 2 = 9.6%• Int-low 1 = 3.8%• Low 0 = 1.5%
VTE @6mo IPD (van Es)• High = 9.8%• Low-int = 6.4%• High vs. non-high OR
• Non-lung = 3.2• Lung = 1.2
![Page 7: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/7.jpg)
Khorana vs. other VTE RAMs: The best of a bad bunch?
Khorana, Lancet 2018
![Page 8: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/8.jpg)
Thromboprophylaxis is effective in cancer outpatients
Ben Aharon, Acta Oncol 2014; Di Nisio, Cochrane 2016
![Page 9: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/9.jpg)
ASCO & ISTH suggest/recommend TP in high risk outpatients, BUT
Key, JCO 2019; Farge, Lancet Oncology 2019
When is the risk high enough to justify thromboprophylaxis (TP)?
![Page 10: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/10.jpg)
Double blind RCT of apixaban vs. placebo for VTE thromboprophylaxis
Carrier, NEJM 2019
![Page 11: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/11.jpg)
Less thrombosis with apixaban (ITT analysis)
Carrier, NEJM 2019
NNT in ITT = 16• 4.2% apixaban• 10.2% placebo
• HR 0.41• 95% CI: 0.26-0.65
![Page 12: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/12.jpg)
More major bleeding with apixaban
NNH on treatment = 100• 2.1% apixaban• 1.1% placebo
• HR 1.89• 95% CI: 0.39-9.24
Carrier, NEJM 2019
NNH in ITT = 57• 3.5% apixaban• 1.8% placebo
• HR 2• 95% CI: 1.01-3.95
![Page 13: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/13.jpg)
CASSINI double blind RCT
• Excluded: – Primary and secondary brain cancers– Hematological malignancies, except lymphoma– Platelets < 50,000 (withhold Rx if < 25)
• Screening LE US: at baseline (4.5% asymptomatic DVT) and every 8 weeks
Khorana, NEJM 2019
![Page 14: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/14.jpg)
Negative Rivaroxaban RCT (CASSINI )
Khorana, NEJM, 2019
NNT = 35
Primary efficacy endpoint @ 180 days
![Page 15: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/15.jpg)
Oral thromboprophylaxis in cancer: summary
• Apixaban and Rivaroxaban reduce VTE rate over 6 months
• Increased major bleeding
• Favorable NNT – NNH ratio
– Apixaban: NNT = 16 | NNH = 57 (100 on treatment)
– Rivaroxaban: NNT = 35| NNH = 101
• Ongoing CANVAS trial (NCT02744092):
– Comparing DOACs, LMWH and warfarin in VTE prophylaxis in cancer
![Page 16: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/16.jpg)
• Suggest3/recommend2/may-use1 DOACs as primary thromboprophylaxis
– starting chemotherapy | Khorana score ≥2
– no drug‐drug interactions | No high risk for bleeding
– up to 6 months
• Suggest LMWH, if concern over DOACs and thromboprophylaxis considered
• ITAC recommends LMWH for pancreatic cancer (grade 1B) 2
TP in ambulatory cancer pts: ISTH/ITAC/ASCO Guidelines
1Wang, JTH 2019; 2Farge, Lancet Oncol 2019; 3Key, JCO 2019
![Page 17: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/17.jpg)
Case #2
• 50 year old female with no prior medical Hx
• Newly diagnosed IgG-Kappa multiple myeloma– Pathological fracture of Rt femur with internal fixation > 1 month ago
– Mobility restored
– Starting RVd as an outpatient
• ECOG1 | BMI = 27
• WBC = 7K/µL | PLT = 150K/µL | Hb = 10.2 gr%
• Creatinine, liver enzymes = normal; Hypoalbuminemia
• PTT, PT, Fibrinogen normal
Thrombotic risk? Thromboprophylaxis indicated? If so, which?
![Page 18: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/18.jpg)
Risk of ATE and VTE in multiple
myeloma
1Cornell, Frontiers in Oncology 2019
![Page 19: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/19.jpg)
VTE risk prediction in MM: IMPEDE-VTE
Sanfilippo, Am J Hem 2019
![Page 20: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/20.jpg)
VTE risk prediction in MM: IMPEDE-VTE
Sanfilippo, Am J Hem 2019; Chalayer, Am J Hem 2019
![Page 21: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/21.jpg)
Type of thromboprophylaxis in MM with len1/thal2-based Rx
1Larocca, Blood 2012 2Palumbo , JCO 2011
![Page 22: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/22.jpg)
Oral thromboprophylaxis in IMID-treated multiple myeloma
• Phase 2 pilot studies suggest safety and efficacy of apixaban (N=50-104) 1,2
– Myelaxat: DVT in 2/104; MB in 1/104; CRNMB in 11/104 2
• Numerically lower bleeding rates in LMWH vs. ASA RCTs– No major bleeding (0/342); 1/342 minor bleeding 3
– Major bleeding in 3/667; 10/667 minor bleeding 4
• Ongoing studies:– Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18]
1Cornell, BJH 2020; 2Pegourie, Am J Hem 2019; 3Larocca, Blood 2012; 4Palumbo , JCO 2011
![Page 23: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/23.jpg)
TP of outpatients with MM: ITAC and ASCO Guidelines
• Immunomodulatory drugs & steroids or other systemic anticancer therapy
– Pharmacologic thromboprophylaxis is recommended (Grade 1A) 1,2
– Aspirin or LMWH for lower-risk patients and LMWH for higher-risk patients 2
• ITAC: low dose VKA also an option
• ME: Consider using IMPEDE-VTE to assess thrombotic risk– HAS-RISc being validated
1Farge, Lancet Oncol 2019; 2Key, JCO 2019
![Page 24: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/24.jpg)
What is the thrombotic risk in acute myeloid leukemia (AML)?
1Libourel, Blood 2016; 2Mitrovic, Thrombosis Res 2015
Any thrombosis
Venous thrombosis
Arterialthrombosis
Median follow up
Younger adults1
(18-65 yrs); n=272
8.7% 4.7% 4% 478 days
Elderly adults1
(>60 yrs); n=132
10.4% 4.4% 5.9% NS
• Most thrombotic events (66%) occurred before the 2nd course of chemotherapy
• Risk may be even higher in acute promyelocytic leukemia2
![Page 25: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/25.jpg)
A high D-dimer level predicts ATE/VTE in newly diagnosed AML
1Libourel, Blood 2016
![Page 26: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/26.jpg)
What is the thrombotic risk in ALL?
Rank, Blood 2018
• Cumulative incidence: 7.9% (6.6-9.1%) over 2.5 yrs• Risk factors: age > 10yrs; mediastinal mass at Dx;
enlarged lymph nodes.
![Page 27: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/27.jpg)
VTE rate remains high despite LMWH prophylaxis in ALL + ASP
1 Sibai, BJH 2020; 2 Orvain, Blood 2020
• LMWH reduces VTE rate but probably not sufficient 1
• VTE incidence of 16% despite prophylactic measures 2
![Page 28: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/28.jpg)
1Greiner, Haematologica 2019; 2Male, Haematologica 2019; 3O’Brien, Thrombosis Haem 2019
THROMBOTECT1 takes the lead in ALL 2
• Apixaban prophylaxis being assessed in children with ALL and CVC (PREVAPIX-ALL) 3
![Page 29: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/29.jpg)
Overview1. Preventing thrombosis in cancer outpatients
2. Treating cancer-associated VTE
– DOAC vs. LMWH
– Treatment duration
3. Practical aspects of AC management (in CAT)
4. Treating recurrent VTE
5. Arterial thrombosis in cancer
![Page 30: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/30.jpg)
Higher risk of recurrent thrombosis in VTE & cancer (vs. no cancer)
Prandoni, Blood, 2002
![Page 31: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/31.jpg)
Case #3
• 51 year old male with morbid obesity (125 kg)
• Newly diagnosed colon cancer– Hemicolectomy and wedge resection of antrum due to suspected GIST in 7/2019
• Post-operative PETCT (8/2019)– Incidental bilateral pulmonary embolism and Lt leg DVT
– Breast mass, compatible with breast cancer – for investigation
• SMA, CBC and PT-PTT-FIB unremarkable
Which anticoagulant?
![Page 32: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/32.jpg)
CLOT1
32
Why LMWH for cancer-associated thrombosis?
1Lee et al. N Engl J. Med. 2003; 2Lee et al. Jama. 2015
CATCH2
![Page 33: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/33.jpg)
DOACs in Cancer associated VTE
1 Young, JCO 2018; 2 Raskob, NEJM 2017; 3McBane, JTH, 2019; 4Agnelli, NEJM 2020
Eliquis
ADAM VTE 3, Caravaggio 4
Rivaroxaban Select-d 1
Edoxaban
Hokusai-Cancer 2
Dalteparin(CLOT regimen)
![Page 34: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/34.jpg)
Young, JCO 2018
...אבל, כרוך בפחות אירועים תרומבוטיים חוזריםxareltoטיפול ב , בסרטן
![Page 35: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/35.jpg)
Young, JCO 2018
xareltoיותר דימום עם
![Page 36: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/36.jpg)
Raskob, NEJM 2017
Hokusai-Cancer
![Page 37: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/37.jpg)
Hokusai-Cancer
Raskob, NEJM 2017
![Page 38: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/38.jpg)
• Select-d: Rivaroxaban (vs. dalteparin)
– ↓ recurrent VTE
– ↑ bleeding
DOACs in Cancer associated VTE
Young, JCO, 2018
Outcome (6 months) Dalteparin (95% CI) Rivaroxaban (95% CI) HR (95% CI)
VTE recurrence 11% (7-16%) 4% (2-9%) 0.43 (0.19-0.99)
Major bleeding 4% (2-8%) 6% (3-11%) 1.83 (0.68-4.96)
Clinically relevant non-major bleeding
4% (2-9%) 13% (9-19%) 3.76 (1.63-8.69)
![Page 39: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/39.jpg)
Increased bleeding with DOACs especially in GI cancers
• Where?– Upper GI major bleeding (in all GI cancers) 2
• Select-d amended to exclude gastroesophageal cancers1
– Urothelial CRNMB 1
• Why?– Intraluminal tumors and post-operative bleeding– Mucosal toxicity associated with anticancer therapy (e.g. 5-FU)?
• Who is at risk?– GI cancer – Urothelial cancer ± nephrostomy– Additional bleeding risk factors 2
1Young, JCO 2018; 2Raskob NEJM 2018; 3Kraaijpoel, Thromb Haem 2018
![Page 40: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/40.jpg)
Are all major bleeds equal in Hokusai-cancer?
Kraaijpoel, Thrombosis & Haemostasis, 2018Cancer Associated Thrombosis Work Group40
More upper GI bleeding, in all types of GI cancer (including pancreas & hepatobiliary)
![Page 41: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/41.jpg)
Apixaban for VTE in cancer
Agnelli, NEJM 2020
![Page 42: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/42.jpg)
Hokusai, Select-d & Carravagio meta-analysis
Mulder, Blood 2020
![Page 43: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/43.jpg)
• Type of VTE
– Upper limb DVT & Catheter related thrombosis
– DVT in unusual sites (sinus vein thrombosis/ splanchnic vein thrombosis etc...)
• Hematological malignancies (esp. acute leukemia) & brain cancer
• Thrombocytopenia (platelets < 50-100K)
• Concomitant drug use
– Antiplatelet drugs (except aspirin 75mg)
– Inhibitors/inducers of PGP / CYP3A4
• CKD ≥ stage IV (eGFR <30 ml/min)
• eGFR 30-50 in only 7.3% in Hokusai-cancer 1
Not enough data for specific populations
1Raskob, NEJM 2018
![Page 44: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/44.jpg)
ISTH SSC Guidance statement for acute CAT 1
• Low risk of bleeding & no drug–drug interactions (DDI’s) → Specific DOACs
• High bleeding risk ± DDI’s Prefer → LMWH
• Shared decision-making:
– Reduction in recurrence but higher bleeding rates with specific DOACs
• Patient values to consider 2
– No interference with cancer treatment | Efficacy
– Safety | Oral administration over injection | Price
• Similar recommendations from ITAC3 and ASCO4
1Khorana, JTH 2018; 2Noble, Haematologica, 2015; 3Farge, Lancet 2019; 4Key, JCO 2019
![Page 45: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/45.jpg)
“Rather than view the DOACs as an oral revolution sent to
usurp the evil injections of LMWH, we should consider them
welcome additions to our armory against CAT”
Noble, Thrombosis Res, 2018
![Page 46: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/46.jpg)
Approaching AC decision after 3-6 months Rx for VTE
Rodger & Le Gal, Blood adv 2018
![Page 47: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/47.jpg)
• Don’t routinely use extended lower dose DOAC Rx in CAT
– Ongoing trials of Apixaban 5mg bid vs. 2.5mg for 12 mo., after 6 mo. CAT Rx
• API-CAT (NCT03692065): Breast, prostate, colon- rectum
• EVE-Extended (NCT03080883): All histologies
• Case fatality from recurrent VTE appears higher than from major bleeding1
• Fatal rec. VTE in cancer = 1.9/100 pys | rec. VTE Case fatality rate = 14.8%
• Fatal MB in cancer = 0.8/100 pys | MB Case fatality rate = 8.9%
• Different balance compared to some estimates from non-cancer patients
Little is known on DOACs in CAT beyond 6-12 months
1Abdulla A…… Lee AYY, Thrombosis Haemostasis 2020
![Page 48: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/48.jpg)
CAT pts alive at 6 mo. remain at high risk of rVTE, CRB and death
1Schmidt…… Lee AYY, Thrombosis Res 2020
![Page 49: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/49.jpg)
Napolitano, JCO 2014
Consider residual vein thrombosis?
Cancer-DACUS study
![Page 50: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/50.jpg)
Jara-Palomares, Br J cancer 2018
Risk adapted model using d-dimer and Hs-CRP?
![Page 51: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/51.jpg)
• Minimum of 3 months for acute DVT and 6 months for acute PE 1
• Continue if 1:
– Metastatic disease or progressive cancer
– Requires ongoing chemotherapy or a thrombogenic regimen
– Previous history of VTE or high-risk cancer
• Promising investigational biomarkers:
• Residual vein thrombosis2; d-dimer and CRP3
When to discontinue AC in CAT?
1Lee, Blood, 2017; 2Napolitano, JCO 2014; 3Jara-Palomares, Br J cancer 2018
![Page 52: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/52.jpg)
Overview1. Preventing thrombosis in cancer outpatients
2. Treating cancer-associated VTE
3. Practical aspects of AC management (in CAT)a. High bleeding risk; Thrombocytopenia
b. Drug-drug interactions; High body weight; Bariatric surgery;
c. Indications for monitoring drug levels
4. Treating recurrent VTE
5. Arterial thrombosis in cancer
![Page 53: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/53.jpg)
Practical aspects of DOAC management (in CAT)
• Assess nausea/vomiting potential & thromboembolic risk– “Just in case” LMWH prescription vs. switching to LMWH 1
• Consider LMWH over DOACs if invasive procedures anticipated soon– 24hr vs. 48hr break
• Assessing bleeding risk
• Thrombocytopenia: avoid if platelets are/expected < 50-100K
• DOAC-drug interactions– Anti-cancer, Anti-emetic; Anti-convulsive
1Riess, The Oncologist, 2018
![Page 54: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/54.jpg)
Case #3 - continued
• 51 year old male with morbid obesity (125 kg)• Colon cancer
– Hemicolectomy and wedge resection of antrum due to suspected GIST in 7/2019
• Incidental bilateral pulmonary embolism and Lt leg DVT– LMWH treatment for two months | Did not tolerate treatment– Apixaban started (reluctantly) | DOAC levels requested but not done
• 3 weeks after starting apixaban (5mg*2) treatment– Recurrent iliofemoral DVT
• Almost unmeasurable apixaban levels at trough at the time of event– Patient reports full adherence to apixaban
Reason/s for failure? Proposed management - TBD later
![Page 55: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/55.jpg)
DOACs in high body weight
• Pharmacokinetic studies suggested lower peak and trough concentrations associated with HBW
• ISTH GLs recommend against DOACs when BMI > 40 or weight > 120kg1
• Recent data suggest comparable safety of DOAC and VKA in HBW2
– For VTE and AF
1Martin, JTH 2016; 2Kushnir, Lancet Haematol 2019
![Page 56: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/56.jpg)
DOACs generally avoided in patients with upper GI surgery
Martin, Am J Med 2017
![Page 57: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/57.jpg)
Criteria for DOAC dose-reduction in Acute VTE
Shulman, Blood 2017
||In the European product monograph for rivaroxaban “increased risk of bleeding”:• Patients with uncontrolled severe arterial hypertension• Receiving concomitant treatment affecting hemostasis.
Labeled enoxaparin dose reduction if eGFR < 30ml/min = 1mg/kg once daily
![Page 58: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/58.jpg)
DOAC dosing in VTE (eGFR<30): ESC PE guidelines1
• Dabigatran is not recommended in patients with CrCl <30 mL/min.
• Edoxaban should be given at a dose of 30 mg OD in CrCl 15 - 50 mL/min – not recommended in patients with CrCl <15 mL/min.
• Rivaroxaban and apixaban used with caution in CrCl 15 - 29mL/min,– not recommended in patients with CrCl <15 mL/min.
• Anticoagulation in hemodialysis or ESRD<15 is a complicated issue – Reviewed elsewhere2
1Konstantinides, Eur Heart J 2019; 2Konigsbrugge and Ay, RPTH 2019
![Page 59: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/59.jpg)
Bleeding (but not VTE) risk is increased when eGFR < 30
Catella, JTH 2020Ongoing clinical trial for VTE and GFR < 30: VERDICT trial, NCT02664155
![Page 60: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/60.jpg)
DOAC dose in AF and advanced renal disease (eGFR<30)
1Konigsbrugge and Ay, RPTH 2019
![Page 61: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/61.jpg)
Inappropriate DOAC dosing in AF leads to adverse outcomes
Yao, JACC 2017
![Page 62: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/62.jpg)
Assessing the bleeding risk in cancer patients with AC
• Risk of bleeding is increased in cancer patients receiving AC for VTE 1,3
• Presentation and course of AC-associated bleeding are not more severe in cancer 2
• Risk factors for AC-associated bleeding in cancer
– CKD ≥ stage III 3 | Platelets < 100K x 109/L 3
– Metastases 3 | GI primary 3
– Age > 75 yrs 4 | Intracranial malignancy (extracranial bleeding) 4
– 1⁰ brain cancer (ICH) 5
• Pilot data supporting safety of DOACs vs. LMWH in 1⁰ & 2⁰ brain cancer 6
1Prandoni, Blood 2002; 2Kraaijpoel, Thromb Haem 2018; 3Angelini, Am J Hem 2019; 4Kamphuizen, JTH 2018; 5Mantia, Blood 2017; 6Carney, JTH 2019
![Page 63: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/63.jpg)
Case #4
• 41 year old female with no prior medical Hx
• Multifocal Glioblastoma multiforme diagnosed ~2 months earlier– Completed radiotherapy. One week into 2nd temozolomide course.
– 6 temozolomide courses planned
• Newly diagnosed iliofemoral deep vein thrombosis
• Unremarkable CBC and SMA
Anticoagulation? If so, which? IVC filter?
![Page 64: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/64.jpg)
High risk of ICH (± LMWH) in 1⁰ and 2⁰ brain cancer
• 14.7% to 22% had major ICH @ 1 year 1,2
– Highest risk: Renal cell carcinoma and melanoma 1
• No increase in major ICH with LMWH in brain metastases 1
• Increased major ICH with LMWH in 1⁰ brain tumors (HR 3.37 to 13.26) 2
– ICH → inferior OS
– PANWARDS to stratify bleeding risk??
• Hypothesis-generating data supporting safety of DOACs vs. LMWH 3,4
1Donato, Blood 2015; 2Mantia, Blood 2017; 3Carney, JTH 2019; 4Raskob, NEJM 2018
![Page 65: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/65.jpg)
DOACs may be comparable to LMWH in 2⁰ brain cancer• 96 patients with brain metastases (41 DOAC, 55 LMWH)
• Definitive international registry underway
Leader A, Hamulyák EN et al, ISTH 2020 (PB2116)
0 50 100 150 200 250
FUDays
0.000
0.025
0.050
0.075
0.100
0.125
Pro
babi
lity
LMWHDOACType of anticoagulant at study index
Cumulative Incidence Functions
0 50 100 150 200 250
FUDays
0.000
0.025
0.050
0.075
0.100
0.125
Pro
babi
lity
LMWHDOACType of anticoagulant at study index
Cumulative Incidence Functions
HR 0.77 (95% CI: 0.23-2.59)
for DOAC vs. LMWH
Pro
bab
ilit
y o
f an
y I
CH
![Page 66: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/66.jpg)
Case #4 - continued
• 41 year old female with no prior medical Hx
• Multifocal Glioblastoma multiforme diagnosed ~2 months earlier
• Newly diagnosed iliofemoral deep vein thrombosis– LMWH started
• 2 weeks into LMWH treatment (day 18 of temozolomide course):
– Platelets = 10,000/micL
– HIT immunoassay negative
– No bleeding
Management?
![Page 67: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/67.jpg)
Managing antithrombotic therapy in thrombocytopenia1
• Thrombocytopenia does not reduce the risk of recurrent arterial/venous thrombosis
• Threshold for changes in anticoagulation = 50,000/µL
– Lower for single antiplatelet therapy (APT) = 20-30,000/µL?? 2
• High bleeding risk
– 30-day bleeding rate (17%) >> arterial TE in AF and plt<50K (3%) 3
• Lower thrombotic risk: non-acute VTE, Catheter-related thrombosis, low risk AF
• High thrombotic risk in acute VTE (i.e. < 30 days)
• Options: Hold | Reduce dose | Continue ± ↑ platelet transfusion threshold
1Leader, Crit Rev Oncol Hematol 2018; 2Feher, Oncologist 2017; 3Livneh…. Leader, under review 2020
![Page 68: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/68.jpg)
Managing antithrombotics in thrombocytopenia (2)
CAT and thrombocytopenia, ISTH guidelines 1
• Acute CAT & platelets < 50,000/µL
– high thrombotic risk: Full LMWH with platelet Tx (target ≥ 40-50,000/µL)
– lower thrombotic risk or sub-acute/chronic CAT
• Platelets 25-50,000/µL: Reduce LMWH dose
• Platelets < 25,000/µL: Hold
• DOACs when platelets < 50,000/µL : May not be appropriate
1Samuelson-Bannow, JTH 2018
![Page 69: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/69.jpg)
We really don’t know, and there is reason to exercise caution, because:
1. Patients with platelets < 100K (Riva) or < 50K (apix/edox) excluded
2. Increased clinically rel. and/or major bleeding with edoxaban and rivaroxaban1,2
– ISTH guidance suggests LMWH over DOAC for CAT with high risk of bleeding3
3. Increased major bleeding with prophylactic DOAC doses vs. placebo in cancer4,5
4. No cohorts of DOAC use in CAT and thrombocytopenia
Can DOACs be safely used for CAT in thrombocytopenia?
1Young, JCO 2018; 2Raskob, NEJM 2018; 3Khorana, JTH 2018;4Carrier, NEJM 2019; 5Khorana, NEJM 2019
![Page 70: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/70.jpg)
MATTER study
NCT03288441
– Population: Hematological malignancy, platelets < 50,000/L & antithrombotic Rx
1. Incidence and predictors of bleeding and thrombosis?
2. Optimal management strategy?
– Design: Prospective observational cohort study (FU = 30 days)
a) Variables: Management and markers of hemostasis at baseline
b) Primary outcome: Composite of major bleeding and thrombosis
• 18 Centers in the Netherlands, Italy, Israel and USA (260 enrolled from 19 centers)
• Interim analysis: August 2020 (N_target = 300)
![Page 71: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/71.jpg)
Case #4 - continued
• 41 year old female with no prior medical Hx
• Multifocal Glioblastoma multiforme diagnosed ~4 months earlier
– Good response (MRI) | Temozolomide dc’d and TCP resolved
– Receiving carbamazepine due to seizures
• Iliofemoral deep vein thrombosis ~2 months earlier– LMWH Rx
• LMWH poorly tolerated. Patient read about DOACs.
DOACs viable option? Any issues?
![Page 72: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/72.jpg)
Interactions between DOACs & cancer Rx are a concern
• DOACs are substrates of P-gp and/or CYP3A4
– PgP/CYP3A4 inhibited or induced by some targeted cancer therapies.
• ↑ bleeding and thrombosis in non-cancer with DOAC & CYP3A4/PgP Inh’s 1,6
– Signal of ↑ bleeding with edoxaban and strong PGP inh. in cancer 2
• Interactions may be clinically relevant1,2 →→ under investigation (TacDOAC registry)
• Drug-drug interactions (DDIs) influence choice of anticoagulation in cancer 3,4
• No theoretical concern that DOACs affect anti-cancer medication 5
1Momin, Eur Heart J 2017; 2Raskob, NEJM 2018 (supp); 3Khorana, JTH 2018; 4Delluc, JTH 2019; 5Reiss, Criticial Rev Oncol/hematol 2018; 6Bellesoeur, Criticial Rev Oncol/hematol 2018
![Page 73: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/73.jpg)
Selected drug-drug interactions with DOACs
1Witt, Blood advances 2018
![Page 74: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/74.jpg)
Selected drug-drug interactions with DOACs in cancer
Lee, Blood 2013; Bellesoeur, Criticial Rev Oncol/hematol; 2018 Kraaijpoel, Blood 2018; Mosarla, JACC 2019
emend
![Page 75: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/75.jpg)
Management of potential DDIs (in cancer)• ASH 2018 VTE GLs1: use alternative anticoagulant rather than DOAC, IF
– Inhibitors or inducers of P-glycoprotein (P-gp)– Strong inhibitors or inducers of cytochrome P450 (CYP) enzymes
• What are the culprit drugs? – Non-inclusive lists exist | high level of suspicion and consult pharmacologist
• Consider renal & hepatic function, type of interaction and indication, in decision making
• Options | Consult specialist1. Alternative anticancer/supportive medication or alternative anticoagulation2. Measure DOAC levels??
→ No dose adjustment data available→ Let’s discuss
1Witt, Blood advances 2018
![Page 76: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/76.jpg)
Assays for DOAC drug level measurement
Connors J, Blood 2018
![Page 77: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/77.jpg)
My two cents worth on DOAC drug level measurement
• High inter and intraindividual variability
• Wide ranges for peak and trough values– Dabigatran levels not superior to clinical criteria for dose reduction1
• Hypothesis-generating data suggest that trough and peak DOAC levels may be associated with adverse clinical outcomes in selected non-cancer patients3,4
• ASH guidelines currently against anticoagulant monitoring for LMWH/DOAC5
• Levels can mainly give red or green lights, combined with the clinical context
• Potential utilities– Absorption issues | Theoretical drug-drug interactions | ESRD | Extremes of body weight
– Treatment failure | Possibly to guide use of antidotes when timing is borderline
1Chan, JTH 2015; 2Connors J, Blood 2018; ; 3Testa, JTH 2018; 4Testa, JTH 2019; 5Witts, Blood advances 2018
![Page 78: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/78.jpg)
ISTH SSC on Hemostasis and malignancy
International registry on DOACs and targeted cancer RxRabin sub-study on DOAC levels
Category (disease commonly used) Medications
BTK inhibitors (CLL and lymphoma) Ibrutinib
Acalbrutinib
BCR-ABL inhibitors (CML) Imatinib
Nilotinib
EGFR, ALK inhibitors (lung cancer) Osimertinib
Alectinib
HER2 inhibitors (breast cancer) Lapatinib
Cyclin-dependent kinase inhibitor (breast
cancer)
Palbociclib
BRAF inhibitor (melanoma) Vemurafenib
VEGF inhibitors (various cancer) Sunitinib
Cabozantinib
mTOR inhibitor (various cancer) Everolimus
![Page 79: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/79.jpg)
Treating CAT: Summary
Ay, Ann Oncol 2019Don’t routinely use reduced-dose (“extended”) DOAC in CAT
Also see ISIM guidelines
![Page 80: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/80.jpg)
Overview1. Preventing thrombosis in cancer outpatients
2. Treating cancer-associated VTE
3. Practical aspects of AC management (in CAT)
4. Treating recurrent VTE
5. Arterial thrombosis in cancer
![Page 81: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/81.jpg)
Case #3 - continued
• 51 year old male with morbid obesity (125 kg)• Colon cancer
– Hemicolectomy and wedge resection of antrum due to suspected GIST in 7/2019
• Incidental bilateral pulmonary embolism and Lt leg DVT– LMWH treatment for two months | Did not tolerate treatment– Apixaban started (reluctantly) | DOAC levels requested but not done
• 3 weeks after starting apixaban (5mg*2) treatment– Recurrent iliofemoral DVT
• Almost unmeasurable apixaban levels at trough at the time of event– Patient reports full adherence to apixaban
Proposed management?
![Page 82: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/82.jpg)
Shulman, Blood 2017Approach to recurrent VTE on AC
![Page 83: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/83.jpg)
1Shulman, Blood 2017; 2Farge, Lancet Oncol 2019; 3Key, JCO 2019
Treating recurrent VTE in cancer
Or switch to DOAC2
IVC filter is a weak recommendation by
some3
![Page 84: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/84.jpg)
Do’s and don’ts with breakthrough VTE
Shulman, Blood 2017
![Page 85: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/85.jpg)
Overview1. Preventing thrombosis in cancer outpatients
2. Treating cancer-associated VTE
3. Practical aspects of AC management (in CAT)
4. Treating recurrent VTE
5. Arterial thrombosis in cancer– Ischemic stroke | MI | peripheral thromboembolism
– Acute thrombotic events in active cancer
– NOT discussed: CV morbidity in cancer survivors
![Page 86: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/86.jpg)
• 68 year old female
31/1/2019: Metastatic gastric adenocarcinoma
6/3/2019: Ischemic stroke – ESUS → Full dose Enoxaparin
13/3/2019: Upper GI bleeding and Type 2 MI → Enoxaparin stopped
18/3/19: 1st line FOLFOX started
21/3/2019: Recurrent upper GI bleeding → Palliative radiotherapy
2/5/19: Pulmonary embolism & splenic infarct → Full dose Enoxaparin
Is outpatient treatment with a DOAC an option?
Case #5
![Page 87: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/87.jpg)
Increased arterial thrombosis risk in newly diagnosed cancer
Navi, JACC 2017
279,719 pairs
![Page 88: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/88.jpg)
• ↑ ischemic stroke1 | ↑ myocardial infarction 1
– HR 2.2, 95% CI: 2.1-2.3 1
– Overall: up to 4.7% (95% CI: 4.6-4.8%) at 6 months 1,2
• ~ Resolved at 1 year 1
• High risk of recurrent ATE after ischemic stroke 3,4
– 16% recurrent stroke at 6 months
• Overall, ATE < VTE (2.6% vs. 8.4%) 2 | ATE = VTE in high risk cancers 2
• Associated with increased mortality (HR ~ 3) 1,3
– vs. non-cancer 1 | vs. no ATE 2
Arterial thromboembolism (ATE) in Cancer
1Navi, JACC 2017; 2Grilz, Haematologica 2018; 3Navi, Neurology 2014; 4Parikh, J Stroke Cerebrovasc Dis 2017;
![Page 89: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/89.jpg)
Lung, RCC, MPN
Male, ↑ Age, Smoking, HTN
Factors associated with arterial thrombosis in cancer
1Navi, J Am Coll Cardiol 2017; 2Grilz, Haematologica 2018
Arterial thrombosis
Cancer type
Cancerbiology
CV risk factors
Anti-cancer drugs
Cancer stage
![Page 90: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/90.jpg)
Drugs associated with arterial thrombosis in cancer
1Choueiri, JCO 2010; 2Scappaticci, JNCI 2007; 3Jain, blood adv 2019; 4Aronson, Thr Res 2018;5Haque, Jama Oncol 2016; 6Abdel-Qadir, Eur J Cancer 2016; 7Tully, Cancer 2016; 8Proverbs-Singh, JNCI 2012
Anti-VEGF Rx 1,2
(e.g. bevacizumab, sunitinib, sorafenib)
BCR-ABL TKIs 3
(ponatinib, nilotinib, dasatinib)
Immunomodulators4
(e.g. thalidomide, lenalidomide)
Aromatase inhibitors 5,6
Platinum-basedchemotherapy
(cisplatin) 7,8
![Page 91: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/91.jpg)
• Treatment 1
– Anticoagulation? | Especially if NBTE not ruled out
– Antiplatelet?
• Prospective randomized pilot study in cancer-associated ischemic stroke 2
• Prevention
– For high risk patients?
• E.g. Prior ATE, CV risk factors
How to manage cancer-associated arterial thrombosis?
1Dardiotis, Int J Onc 2019; 2NCT01763606
![Page 92: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/92.jpg)
• Patients with ATE have an increased risk of undiagnosed cancer 1,2,3
– Up to 3.5% (95% CI: 3-3.9%) at 12 months 1 | Esp. in 6 months after ATE
• RR highest in unexplained ATE 3 (up to 3.49)
– age≤50 years
– no prior cardiovascular (CV) disease
– no modifiable CV risk factors
• Practice points
– Increase awareness in unsuspected ATE similar to unprovoked VTE
– Screening not routinely recommended
Should we suspect cancer if ATE and no CV risk factors?
1Sundbøll, Circulation 2018; 2Navi, Blood 2018; 3Leader, EHA 2020 (#S325)
![Page 93: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/93.jpg)
• Atrial fibrillation (ISTH GLs: Delluc, JTH 2019)
• NBTE
• Non-thrombotic cancer-associated cardiovascular disease (Cardiomyopathy, HTN)
Beyond the scope of this lecture…..
![Page 94: How I treat my Cancer Associated Thrombosis€¦ · – Thromboprophylaxis in newly diagnosed Multiple Myeloma (TiMM) [2015-002668-18] 1 Cornell, BJH 2020 ; 2 Pegourie, Am J Hem 2019](https://reader034.vdocuments.mx/reader034/viewer/2022050314/5f76e23f2873a0055a6a1ce3/html5/thumbnails/94.jpg)
94
Incidental and subsegmental PEAC in palliative
care settingRabbits
[email protected] | 0544437212
Distal DVT CVCs